Press / media

As an institution of application-oriented research, the Fraunhofer Institute for Cell Therapy and Immunology IZI attaches great importance to informing customers and the public.

Latest press releases


Research team from Göttingen and Halle develops new inhibitors for enzymes

With over 1.2 million people affected in Germany alone and over 50 million people worldwide, Alzheimer's disease, also referred to simply as Alzheimer's, is one of the greatest medical and social challenges of our time. Due to pathological changes in the brain, patients become increasingly forgetful and disoriented as the disease progresses. In the worst cases, even close relatives are no longer recognized and simple household tasks can no longer be carried out independently. This means care is needed for those affected. Despite intensive research, Alzheimer's disease is still considered incurable today. Researchers at the University of Göttingen and the Fraunhofer Institute for Cell Therapy and Immunology Leipzig-Halle have described a promising approach to treating Alzheimer's disease. The results have been published in the journal Biochemistry.
Read more


Prognostic biomarkers for prostate cancer identified

Led by the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, as well as the Department of Urology of the University Hospital and Faculty of Medicine of the Technische Universität Dresden, a team of researchers has succeeded, for the first time, in identifying prognostic biomarkers for prostate cancer which are based on transcriptome-wide gene sequencing. The description of the developed gene signature for the assessment of prostate cancer after surgery has now been published in the renowned “European Urology” journal.
Read more


Astacin Proteases Unit established at Fraunhofer IZI

On 20th May 2020, the Astacin Proteases junior working group started its work at the Fraunhofer Institute for Cell Therapy and Immunology (IZI). This group, which is headed by Dr Daniel Ramsbeck, primarily focuses on the design and development of meprin inhibitors and the development of ovastacin inhibitors. The research group will be funded by the Investitionsbank Sachsen-Anhalt (using funds from the European Regional Development Fund (ERDF)) for a period of roughly two years.
Read more


Patented Fraunhofer IZI technology facilitates specific Dengue virus diagnostics

A new technology developed by the Fraunhofer Institute for Cell Therapy and Immunology (IZI) facilitates a specific, sensitive diagnosis of the Dengue virus. The patented procedure has been licensed to two companies and corresponding antibody tests are now available on the market. As a result, both the four different Dengue virus serotypes can be differentiated and also the Dengue virus itself can be distinguished from other closely related flaviviruses, which include the yellow fever virus and tick-borne encephalitis virus, in addition to the Zika virus and the West Nile virus. Moreover, work is already underway to adapt the procedure to the SARS-CoV-2 virus and the West Nile virus.
Read more

Archive press releases

RSS Newsfeed

Get the latest news about the Fraunhofer IZI. Through our RSS-feed you have the opportunity to follow all our press releases and receive them right when they are published.

Social media


Media library